Raghavendra Gowda

Raghavendra Gowda, MS, Ph.D., is a Senior Advisor in Toxicology at Eli Lilly and Company, where they lead nonclinical safety for gene therapeutics focused on neurodegenerative diseases. With a strong background in pharmaceutical science, Raghavendra has previously held positions as a Senior Scientist in Preclinical Toxicology and Assistant Professor of Pharmacology. They completed their Ph.D. in Biochemistry at the University of Mysore, and their extensive experience includes roles at Eurofins Product Safety Labs, Penn State Milton S. Hershey Medical Center, and Penn State University. Raghavendra's expertise encompasses toxicology, gene therapy, and innovative drug discovery, contributing to numerous published research articles and patent innovations in the field.